<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 OR 15(d) off
The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event
reported): <B>January 3, 2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CANNABIS SCIENCE, INC.</U></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified
in charter)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 0.8pt; text-decoration: underline; line-height: 115%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Nevada</U></B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 0.8pt; text-decoration: underline; line-height: 115%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>000-28911</U></B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 0.8pt; text-decoration: underline; line-height: 115%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>91-1869677</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><B>19800 MacArthur Blvd., Suite
        #300</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><B><U>Irvine, California</U></B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; padding-right: 0.8pt; text-decoration: underline; line-height: 115%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>92612</U></B></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;(Address of principal executive offices)&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 4.75in">&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>1-888-263-0832</U></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&#9744; Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 1.01 &#9;Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On January 3, 2017 Cannabis Science, Inc. (the &#8220;Company&#8221;),
entered into a Collaborative Research Agreement (the &#8220;Agreement&#8221;) with Dana-Farber Cancer Institute, Inc., (the &#8220;Institute&#8221;)
a Massachusetts not-for-profit corporation, having its principal offices at 450 Brookline Avenue, Boston, MA 02215.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Pursuant to the Agreement the Institute has developed know-how
and expertise in the treatment of cancer and the Company would like to collaborate with the Institute to develop and investigate
the use of Cannabinoids to cure various cancers and obtain from the Institute data and certain rights to inventions that are developed
during research funded by the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">To the degree that the Project is successful, it is
contemplated that Research Results shall be expeditiously disseminated to the public through joint publications. Authorship shall
be based on contributions to the Project, in accordance with academic standards and customs, and proper acknowledgment for each
party&#8217;s contribution shall be made in any presentation or publication reporting Research Results.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Each Party has disclosed and shall retain ownership of their
respective intellectual property (&#8220;IP&#8221;). All rights, title and interest in and to any Inventions conceived and reduced
to practice jointly by the Company and the Institute hereby (&#8220;Joint Inventions&#8221;) shall be jointly owned by the Company
and the Institute. Patent applications with respect to Joint Inventions shall be filed according to the provisions of the agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The term of the Agreement is for one year. In consideration
for this Agreement and performance of the Research, the Company has paid the Institute Two Hundred and One Thousand and Six Hundred
and Fifty-Six dollars (US) ($201,656).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt">Each Party shall have
the right to seek additional third party funding for the Research and in the case of the Company, for commercialization of all
Inventions derived as a result of the Agreement and both parties shall mutually agree on the terms and conditions (outside of the
terms of the Agreement) for any third party research funding.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 8.01&#9;Other Events</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In a press release issued on January 6, 2017, the Company
incorrectly referenced the entity Dana-Faber / Harvard Cancer Center (DF/HCC) with whom it had signed the Agreement. Dana-Farber
Cancer Institute, Inc. is the correct entity the Company has signed the agreement with and that is working collaboratively with
the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CANNABIS SCIENCE, INC.</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 37%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 13%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: white 3pt solid; padding-right: 0.8pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:&nbsp; January 9, 2017</FONT></TD>
    <TD STYLE="border-bottom: white 3pt solid; padding-right: 0.8pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/&nbsp;Raymond C. Dabney</I></FONT></TD>
    <TD STYLE="border-bottom: white 3pt solid; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Raymond C. Dabney, President &amp; C.E.O.</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>

    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "cbis-20170109_8k.htm", "description": "CBIS 8K", "secsgml_size_bytes": 16523}]
{"company-data": {"conformed-name": "CANNABIS SCIENCE, INC.", "cik": "0001024626", "assigned-sic": "2834", "irs-number": "911869677", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28911", "film-number": "17516845"}, "business-address": {"street1": "19800 MACARTHUR BLVD., SUITE #300", "city": "IRVINE", "state": "CA", "zip": "92612", "phone": "1-888-263-0832"}, "mail-address": {"street1": "19800 MACARTHUR BLVD., SUITE #300", "city": "IRVINE", "state": "CA", "zip": "92612"}, "former-company": [{"former-conformed-name": "GULF ONSHORE, INC.", "date-changed": "20080520"}, {"former-conformed-name": "Brighton Oil & Gas, Inc.", "date-changed": "20070927"}, {"former-conformed-name": "Brighton Oil & Gas", "date-changed": "20070927"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) off
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
January 3, 2017
CANNABIS SCIENCE, INC.
(Exact name of registrant as specified
in charter)
Nevada
000-28911
91-1869677
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
19800 MacArthur Blvd., Suite
        #300
Irvine, California
92612
(Address of principal executive offices)
(Zip Code)
1-888-263-0832
Registrant's telephone number
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
1
Item 1.01 	Entry into a Material Definitive Agreement.
On January 3, 2017 Cannabis Science, Inc. (the "Company"),
entered into a Collaborative Research Agreement (the "Agreement") with Dana-Farber Cancer Institute, Inc., (the "Institute")
a Massachusetts not-for-profit corporation, having its principal offices at 450 Brookline Avenue, Boston, MA 02215.
Pursuant to the Agreement the Institute has developed know-how
and expertise in the treatment of cancer and the Company would like to collaborate with the Institute to develop and investigate
the use of Cannabinoids to cure various cancers and obtain from the Institute data and certain rights to inventions that are developed
during research funded by the Company.
To the degree that the Project is successful, it is
contemplated that Research Results shall be expeditiously disseminated to the public through joint publications. Authorship shall
be based on contributions to the Project, in accordance with academic standards and customs, and proper acknowledgment for each
party's contribution shall be made in any presentation or publication reporting Research Results.
Each Party has disclosed and shall retain ownership of their
respective intellectual property ("IP"). All rights, title and interest in and to any Inventions conceived and reduced
to practice jointly by the Company and the Institute hereby ("Joint Inventions") shall be jointly owned by the Company
and the Institute. Patent applications with respect to Joint Inventions shall be filed according to the provisions of the agreement.
The term of the Agreement is for one year. In consideration
for this Agreement and performance of the Research, the Company has paid the Institute Two Hundred and One Thousand and Six Hundred
and Fifty-Six dollars (US) ($201,656).
Each Party shall have
the right to seek additional third party funding for the Research and in the case of the Company, for commercialization of all
Inventions derived as a result of the Agreement and both parties shall mutually agree on the terms and conditions (outside of the
terms of the Agreement) for any third party research funding.
Item 8.01	Other Events
In a press release issued on January 6, 2017, the Company
incorrectly referenced the entity Dana-Faber / Harvard Cancer Center (DF/HCC) with whom it had signed the Agreement. Dana-Farber
Cancer Institute, Inc. is the correct entity the Company has signed the agreement with and that is working collaboratively with
the Company.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CANNABIS SCIENCE, INC.
Date:  January 9, 2017
By:
/s/ Raymond C. Dabney
Raymond C. Dabney, President & C.E.O.
3